Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Avanish Aggarwal

Gastroenterology Orlando, FL Medical Doctor

NPI 1376517128 CMS profile 152573

3885 Oakwater Cir, Orlando, FL 32806

Open in the dashboard

General payments

$7,584

407 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$6,266 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Avanish Aggarwal of Orlando, FL is reported in the CMS Open Payments database as having received $7,584 across 407 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $6,266 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 76th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,770 93
2024 General $1,837 81
2023 General $1,546 81
2022 General $792 45
2021 General $897 55
2020 General $385 26
2019 General $356 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Avanish Aggarwal
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Avanish Aggarwal were reported at $1,770. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Avanish Aggarwal Gastroenterology median Middle half National median
2019 $356 $417 $126–$1,100 $163
2020 $385 $224 $74–$624 $114
2021 $897 $352 $106–$1,054 $132
2022 $792 $448 $129–$1,270 $149
2023 $1,546 $533 $150–$1,390 $160
2024 $1,837 $605 $160–$1,606 $164
2025 $1,770 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,169 140 payments
  2. Janssen Biotech, Inc. $885 39 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $867 39 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $468 27 payments
  5. Gilead Sciences, Inc. $440 24 payments
  6. Pfizer Inc. $374 22 payments
  7. Celgene Corporation $238 18 payments
  8. Nestle HealthCare Nutrition Inc. $222 13 payments
  9. Intercept Pharmaceuticals, Inc. $203 10 payments
  10. Intra-Sana Laboratories $150 1 payment
  11. Other $1,568 74 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,536 405 payments
  2. Education $48 2 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $837 48 payments
  2. LINZESS $700 49 payments
  3. STELARA $641 25 payments
  4. ENTYVIO $603 27 payments
  5. SKYRIZI Immunology $540 33 payments
  6. TREMFYA $525 22 payments
  7. CREON $511 36 payments
  8. XIFAXAN $390 23 payments
  9. SKYRIZI Immunology $286 17 payments
  10. ZENPEP $281 15 payments
  11. Other $4,360 217 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

723

Median for Gastroenterology: 569

Drug cost

$290,173

Median for Gastroenterology: $104,976

Branded share of claims

30.7%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rinvoq Upadacitinib Brand 11 $85,153
Creon Lipase/Protease/Amylase Brand 26 $81,937
Zenpep Lipase/Protease/Amylase Brand 12 $38,469
Linzess Linaclotide Brand 50 $36,953
Vemlidy Tenofovir Alafenamide Brand 12 $19,859
Plenvu Peg3350/Sod Sul/Nacl/Kcl/Asb/C Brand 45 $6,633
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 34 $5,861
Famotidine Generic 204 $4,281
Mesalamine Generic 11 $3,662
Esomeprazole Magnesium Generic 35 $2,177

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$277,605

Of which drugs: $204,628

Medicare patients

329

Average age 73

Services billed

12,986

192 women, 137 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 49%
Ischemic heart disease 37%
Diabetes 31%
Chronic kidney disease 27%
Depression 22%
Cancer 18%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vedolizumab, 1 mg J3380 Office 11 10,200 $172,569

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $179
$179 — —
RINVOQ
  • AbbVie, Inc. $165
$165 11 —
SKYRIZI
  • AbbVie, Inc. $146
$146 — —
TREMFYA
  • Janssen Biotech, Inc. $129
  • Janssen Scientific Affairs, LLC $14
$143 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $111
$111 — 10,200

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

407 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record